We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current CHRS market cap is 95.05M. The company's latest EPS is USD -2.0648 and P/E is -0.40.
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 58.72M | 74.57M | 91.52M | 77.06M | 64.98M |
| Operating Income | -34.54M | -32.01M | -68.91M | -49.73M | -20.51M |
| Net Income | -42.87M | -39.64M | -79.65M | 102.88M | -12.92M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 356.07M | 475.82M | 326.55M | 211.04M | 257.24M |
| Operating Income | 107.77M | 156.32M | -263.86M | -256.88M | -203.2M |
| Net Income | 89.83M | 132.24M | -287.1M | -291.75M | -237.89M |
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 469.59M | 583.78M | 629.6M | 763.55M | 674.86M |
| Total Liabilities | 644.36M | 717.38M | 823.03M | 845.39M | 758.96M |
| Total Equity | -174.76M | -133.6M | -193.43M | -81.84M | -84.11M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 408.93M | 841.65M | 679.33M | 480.85M | 629.6M |
| Total Liabilities | 303.71M | 560.68M | 581.61M | 618.27M | 823.03M |
| Total Equity | 105.21M | 280.97M | 97.73M | -137.42M | -193.43M |
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -107.65M | -161.95M | -174.88M | -46.77M | 12.97M |
| Investing | 58.89M | 109.44M | 144.64M | 202.76M | 230.42M |
| Financing | 58.13M | 69.23M | 69.6M | 887k | -187.04M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | 28.36M | 154.15M | -37.43M | -241.12M | -174.88M |
| Investing | -12.73M | -14.4M | -138.41M | -166.85M | 144.64M |
| Financing | 89.37M | 223.95M | 51.88M | 54.33M | 69.6M |
| Market Cap | 95.05M |
| Price to Earnings Ratio | -0.40 |
| Price to Sales Ratio | 0.37 |
| Price to Cash Ratio | 0.93 |
| Price to Book Ratio | -0.49 |
| Dividend Yield | - |
| Shares Outstanding | 115.21M |
| Average Volume (1 week) | 2.82M |
| Average Volume (1 Month) | 2.81M |
| 52 Week Change | -60.71% |
| 52 Week High | 3.70 |
| 52 Week Low | 0.6603 |
| Spread (Intraday) | 0.03 (4.21%) |
| Company Name | Coherus BioSciences Inc |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.coherus.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
